Genome Med April 2023 PMID 37101291

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers.

Katherine E Hutchinson, Jessica W Chen, Heidi M Savage, Thomas J Stout, Frauke Schimmoller, Javier Cortés, Susan Dent, Nadia Harbeck, William Jacot, Ian Krop, Sally E Trabucco, Smruthy Sivakumar, Ethan S Sokol, Timothy R Wilson

Download social card

Mentions

Peak: 1 in Apr 2023

across 2 sources since Apr 2023

Extended reach

382

potential audience

Total likes

Video views

150

Mentions per month

Apr 2023 – Jul 2023

Where it's discussed

X / Twitter1 posts
YouTube1 videos

AI synopsis

What people are saying

The discussions reflect a positive response, with mentions like 'clonal context matters' and 'better responses,' indicating agreement and interest. The tone is professional and curious, emphasizing the technical aspects and clinical implications, but without fanfare reflecting a moderate overall impact.

AgreementModerate agreement

The posts express support for the study’s findings, emphasizing that clonal PIK3CA mutations are linked to better treatment responses.

InterestHigh interest

The discussion demonstrates high curiosity, with posts highlighting the importance of mutation clonality and its predictive value.

EngagementModerate engagement

Posts show moderate engagement, including recognition of the study's significance and comments on the biological implications.

ImpactModerate impact

The users acknowledge the study's potential to influence treatment decisions, although discussions remain focused on scientific insights rather than broad societal impact.

Abstract in brief

Mutations in the PIK3CA gene, linked to the PI3K pathway, are common in HR+/HER2- breast cancer and can enhance cancer cell sensitivity to specific inhibitors.
Researchers examined circulating tumor DNA (ctDNA) from patients to see how multiple PIK3CA mutations (mut) could predict their response to a treatment combining fulvestrant and taselisib.
The findings suggest that patients with clonal multiple PIK3CAmut had fewer additional genetic alterations and showed a better response and longer survival compared to those with subclonal mutations, indicating the potential of clonal mutations as a biomarker for treatment efficacy.

Read the full abstract

All mentions

Impact of PIK3CA Mutation Clonality on Treatment Outcomes in Breast Cancer

Mutations in the PIK3CA gene are common in ER+/HER2- breast cancer and influence sensitivity to targeted therapies. This study examines circulating tumor DNA to evaluate how multiple PIK3CA mutations impact treatment…

Medicine RTCL TV · Jul 29, 2023 150 views

Ethan Sokol

@EthanSokol · X

Apr 26, 2023 · 6 likes · 232 followers View post →